The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

The collaboration, set to begin on 1 July, will see Novo Nordisk team up with the telehealth company to offer Wegovy to ...

Hims & Hers' (NYSE: HIMS) stock crashed over 30% following news highlighting the end of its relationship with Novo Nordisk ...

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...

Investing.com -- LifeMD Inc (NASDAQ: LFMD) stock rose 4.3% following Novo Nordisk’s (NYSE: NVO) announcement that it will continue its collaboration with the telehealth provider to offer patients ...

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after ...

Why Novo Nordisk is parting ways with Hims & Hers. To catch full episodes of all The Motley Fool's free podcasts, check out ...

This article will be updated throughout the day, so check back often for more daily updates. Since tumbling into bear market ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.1% in the afternoon session after the company's CEO ...

(Reuters) -India’s drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly (NYSE: LLY )’s ...

Novo Nordisk (NYSE: NVO) severed its partnership with Hims & Hers (NYSE: HIMS), arguing that the company breached the ...

For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist.